FIELD: medicine; oncology; nephrology.
SUBSTANCE: group of inventions can be used for treating cancer in patients. That is ensured by oral administration of the combined drug into the patient. Means comprises α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in molar ratio 1:0.5. Patient has creatinine clearance less than 30 ml/min. Agent is administered in dose of 30–50 mg/m2/day in the form of an FTD-equivalent, dividing into two to four doses a day. What is also presented is use of a combined medicinal agent for preparing a therapeutic agent.
EFFECT: group of inventions provides treating cancer in patients with severe renal insufficiency.
14 cl, 1 dwg, 2 tbl, 1 ex
